vs
Side-by-side financial comparison of Gilead Sciences (GILD) and Royal Caribbean Group (RCL). Click either name above to swap in a different company.
Gilead Sciences is the larger business by last-quarter revenue ($7.9B vs $4.3B, roughly 1.9× Royal Caribbean Group). Gilead Sciences runs the higher net margin — 27.5% vs 17.9%, a 9.7% gap on every dollar of revenue. On growth, Royal Caribbean Group posted the faster year-over-year revenue change (13.2% vs 4.7%). Over the past eight quarters, Gilead Sciences's revenue compounded faster (8.9% CAGR vs 1.8%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Royal Caribbean Group, formerly known as Royal Caribbean Cruises Ltd., is a cruise holding company headquartered in Miami, Florida, United States and incorporated in Liberia. It is the world's second-largest cruise line operator, after Carnival Corporation & plc. As of September 2025, Royal Caribbean Group fully owns three cruise lines: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. It also holds a 50% stake in TUI Cruises, which operates Mein Schiff and Hapag-Lloyd ...
GILD vs RCL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $4.3B |
| Net Profit | $2.2B | $762.0M |
| Gross Margin | 79.5% | — |
| Operating Margin | 25.0% | 21.9% |
| Net Margin | 27.5% | 17.9% |
| Revenue YoY | 4.7% | 13.2% |
| Net Profit YoY | 22.4% | 36.3% |
| EPS (diluted) | $1.75 | $2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $4.3B | ||
| Q4 25 | $7.9B | $4.3B | ||
| Q3 25 | $7.8B | $5.1B | ||
| Q2 25 | $7.1B | $4.5B | ||
| Q1 25 | $6.7B | $4.0B | ||
| Q4 24 | $7.6B | $3.8B | ||
| Q3 24 | $7.5B | $4.9B | ||
| Q2 24 | $7.0B | $4.1B |
| Q1 26 | — | $762.0M | ||
| Q4 25 | $2.2B | $753.0M | ||
| Q3 25 | $3.1B | $1.6B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $1.3B | $730.0M | ||
| Q4 24 | $1.8B | $552.0M | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.6B | $854.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 47.4% | ||
| Q3 25 | 79.8% | 51.8% | ||
| Q2 25 | 78.8% | 49.7% | ||
| Q1 25 | 76.9% | 48.0% | ||
| Q4 24 | 79.1% | 45.4% | ||
| Q3 24 | 79.1% | 51.1% | ||
| Q2 24 | 77.8% | 47.6% |
| Q1 26 | — | 21.9% | ||
| Q4 25 | 25.0% | 21.9% | ||
| Q3 25 | 42.8% | 33.1% | ||
| Q2 25 | 34.9% | 29.3% | ||
| Q1 25 | 33.6% | 23.6% | ||
| Q4 24 | 32.4% | 16.6% | ||
| Q3 24 | 11.8% | 33.4% | ||
| Q2 24 | 38.0% | 26.7% |
| Q1 26 | — | 17.9% | ||
| Q4 25 | 27.5% | 17.7% | ||
| Q3 25 | 39.3% | 30.6% | ||
| Q2 25 | 27.7% | 26.7% | ||
| Q1 25 | 19.7% | 18.3% | ||
| Q4 24 | 23.6% | 14.7% | ||
| Q3 24 | 16.6% | 22.7% | ||
| Q2 24 | 23.2% | 20.8% |
| Q1 26 | — | $2.76 | ||
| Q4 25 | $1.75 | $2.76 | ||
| Q3 25 | $2.43 | $5.74 | ||
| Q2 25 | $1.56 | $4.41 | ||
| Q1 25 | $1.04 | $2.70 | ||
| Q4 24 | $1.43 | $2.27 | ||
| Q3 24 | $1.00 | $4.21 | ||
| Q2 24 | $1.29 | $3.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | $825.0M |
| Total DebtLower is stronger | $24.9B | $21.3B |
| Stockholders' EquityBook value | $22.7B | $10.2B |
| Total Assets | $59.0B | $41.6B |
| Debt / EquityLower = less leverage | 1.10× | 2.08× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $825.0M | ||
| Q4 25 | $68.0M | $825.0M | ||
| Q3 25 | $19.0M | $432.0M | ||
| Q2 25 | $69.0M | $735.0M | ||
| Q1 25 | — | $386.0M | ||
| Q4 24 | — | $388.0M | ||
| Q3 24 | — | $418.0M | ||
| Q2 24 | — | $391.0M |
| Q1 26 | — | $21.3B | ||
| Q4 25 | $24.9B | $18.2B | ||
| Q3 25 | $24.9B | $17.2B | ||
| Q2 25 | $24.9B | $17.6B | ||
| Q1 25 | $25.0B | $18.0B | ||
| Q4 24 | $26.7B | $18.5B | ||
| Q3 24 | $23.2B | $19.0B | ||
| Q2 24 | $23.3B | $19.8B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $22.7B | $10.0B | ||
| Q3 25 | $21.5B | $10.1B | ||
| Q2 25 | $19.7B | $9.2B | ||
| Q1 25 | $19.2B | $8.0B | ||
| Q4 24 | $19.3B | $7.6B | ||
| Q3 24 | $18.5B | $7.0B | ||
| Q2 24 | $18.3B | $6.0B |
| Q1 26 | — | $41.6B | ||
| Q4 25 | $59.0B | $41.6B | ||
| Q3 25 | $58.5B | $40.1B | ||
| Q2 25 | $55.7B | $38.5B | ||
| Q1 25 | $56.4B | $37.5B | ||
| Q4 24 | $59.0B | $37.1B | ||
| Q3 24 | $54.5B | $37.1B | ||
| Q2 24 | $53.6B | $37.0B |
| Q1 26 | — | 2.08× | ||
| Q4 25 | 1.10× | 1.81× | ||
| Q3 25 | 1.16× | 1.70× | ||
| Q2 25 | 1.27× | 1.92× | ||
| Q1 25 | 1.30× | 2.26× | ||
| Q4 24 | 1.38× | 2.44× | ||
| Q3 24 | 1.26× | 2.69× | ||
| Q2 24 | 1.28× | 3.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $6.5B |
| Free Cash FlowOCF − Capex | $3.1B | — |
| FCF MarginFCF / Revenue | 39.4% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 1.52× | 8.48× |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $6.5B | ||
| Q4 25 | $3.3B | $1.6B | ||
| Q3 25 | $4.1B | $1.5B | ||
| Q2 25 | $827.0M | $1.7B | ||
| Q1 25 | $1.8B | $1.6B | ||
| Q4 24 | $3.0B | $1.5B | ||
| Q3 24 | $4.3B | $897.0M | ||
| Q2 24 | $1.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $116.0M | ||
| Q3 25 | $4.0B | $-989.0M | ||
| Q2 25 | $720.0M | $910.0M | ||
| Q1 25 | $1.7B | $1.2B | ||
| Q4 24 | $2.8B | $915.0M | ||
| Q3 24 | $4.2B | $563.0M | ||
| Q2 24 | $1.2B | $-567.0M |
| Q1 26 | — | — | ||
| Q4 25 | 39.4% | 2.7% | ||
| Q3 25 | 51.0% | -19.2% | ||
| Q2 25 | 10.2% | 20.1% | ||
| Q1 25 | 24.8% | 30.0% | ||
| Q4 24 | 37.4% | 24.3% | ||
| Q3 24 | 55.2% | 11.5% | ||
| Q2 24 | 17.2% | -13.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 35.4% | ||
| Q3 25 | 1.9% | 47.8% | ||
| Q2 25 | 1.5% | 18.4% | ||
| Q1 25 | 1.6% | 10.7% | ||
| Q4 24 | 1.9% | 14.7% | ||
| Q3 24 | 1.9% | 6.8% | ||
| Q2 24 | 1.9% | 52.1% |
| Q1 26 | — | 8.48× | ||
| Q4 25 | 1.52× | 2.16× | ||
| Q3 25 | 1.35× | 0.93× | ||
| Q2 25 | 0.42× | 1.44× | ||
| Q1 25 | 1.34× | 2.23× | ||
| Q4 24 | 1.67× | 2.66× | ||
| Q3 24 | 3.44× | 0.81× | ||
| Q2 24 | 0.82× | 1.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
RCL
Segment breakdown not available.
